Major Investments and Legal Battles: The Latest in Health and Pharmaceuticals
Merck Animal Health is investing $895 million in its Kansas facility. Novo Nordisk anticipates Wegovy sales recovery post-copycat ban. UnitedHealth faces stock drop post-executive's death. The FDA enforces AI usage; AstraZeneca’s drug price challenge fails. FDA approves Verastem ovarian cancer therapy, enhancing treatment options.
In a significant financial move, Merck Animal Health has announced an impressive $895 million investment to expand its manufacturing facility in De Soto, Kansas. This capital influx includes a substantial $860 million dedication to upgrading the existing site and an additional $35 million for research and development laboratories.
Concurrently, Novo Nordisk remains optimistic about the U.S. sales recovery of its Wegovy weight-loss drug following an FDA-mandated halt on compound copycat productions later this month. This comes as the pharmaceutical giant revises its 2025 financial forecasts.
The health sector also witnessed legal tussles, including a lawsuit against UnitedHealth following an executive's death, and legal support for the FDA's power to delist Eli Lilly's drugs from shortage lists, a move with widespread implications for compounding pharmacies and drug pricing.
(With inputs from agencies.)
ALSO READ
Union Rights Standoff: FDA Workers Left in Limbo
Activist Moves, FDA Changes, and Big Investments Take Center Stage in Health News
Innovative At-Home Cervical Cancer Test Gains FDA Approval Amid Healthcare Shakeups
Leadership Shift at UnitedHealth: Witty Steps Down Amid Cost Concerns
Biotech Firms Rethink Trial Strategies Amid FDA Uncertainties
Google News